Is Johnson & Johnson  Stock a Bargain?

Johnson & Johnson (JNJ) NYSEJohnson & Johnson begin human trials for Coronavirus vaccine as early as July. Alex Gorsky, CEO of Johnson & Johnson announced Wednesday June 10, 2020.

Johnson & Johnson’s seventh Chairman and CEO started his career at the company in 1988 as a sales representative. And that’s just one great fact about Alex Gorsky, whose exceptional leadership skills have helped make Johnson & Johnson a worldwide leader in healthcare. Source: Click Here

Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, said, “Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development of our investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Simultaneously, we are continuing our efforts to build important global partnerships and invest in our vaccine production technology and manufacturing capabilities. Our goal is to ensure we can deliver a vaccine to the world and protect people everywhere from this pandemic.”

The randomized, double-blind, placebo-controlled Phase 1/2a study will evaluate the safety, reactogenicity (response to vaccination), and immunogenicity (immune response) of the investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant in 1045 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older. The study will take place in the U.S. and Belgium.

The Company is in discussions with the National Institutes of Allergy and Infectious Diseases with the objective to start the Phase 3 SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant, clinical trial ahead of its original schedule, pending outcome of phase 1 studies and approval of regulators.


Data by YCharts

[object HTMLElement]

Top 5  Institutional Holders

Holder  Shares  Date Reported  % Out    Value

Vanguard Group, Inc. (The)          233,816,138        Mar 30, 2020      8.87%    30,660,310,175

Blackrock Inc.     192,545,915        Mar 30, 2020      7.31%    25,248,545,833

State Street Corporation               151,549,024        Mar 30, 2020      5.75%    19,872,623,517

Geode Capital Management, LLC               38,965,156           Mar 30, 2020      1.48%    5,109,500,906

State Farm Mutual Automobile Insurance Co       34,574,792           Mar 30, 2020      1.31%    4,533,792,474

Top Mutual Fund Holders

Holder  Shares  Date Reported  % Out    Value

Vanguard Total Stock Market Index Fund              74,147,917           Dec 30, 2019       2.81%    10,815,956,652

Vanguard 500 Index Fund            52,581,325           Dec 30, 2019       2.00%    7,670,037,877

SPDR S&P 500 ETF Trust 30,376,922           Jan 30, 2020        1.15%    4,522,212,378

Vanguard Institutional Index Fund-Institutional Index Fund           23,801,101           Dec 30, 2019       0.90%                3,471,866,602

Fidelity 500 Index Fund 23,219,414           Jan 30, 2020        0.88%    3,456,674,162

CWEB has issued a Buy Rating for Johnson & Johnson (JNJ) NYSEJohnson & Johnson and Price target of $200 is not registered as an investment adviser with the U.S. Securities and Exchange Commission. Rather, relies upon the “publisher’s exclusion” from the definition of investment adviser as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.

Follow us on Google news for more updates and News


This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.